keyword
https://read.qxmd.com/read/30723315/variants-in-vincristine-pharmacodynamic-genes-involved-in-neurotoxicity-at-induction-phase-in-the-therapy-of-pediatric-acute-lymphoblastic-leukemia
#1
JOURNAL ARTICLE
Idoia Martin-Guerrero, Angela Gutierrez-Camino, Aizpea Echebarria-Barona, Itziar Astigarraga, Nagore Garcia de Andoin, Aurora Navajas, Africa Garcia-Orad
Vincristine is an important drug of acute lymphoblastic leukemia (ALL) treatment protocols that can cause neurotoxicity. Patients treated with LAL/SHOP protocols often suffer from vincristine-related neurotoxicity in early phases of treatment. A genetic variant in CEP72, a gene involved in vincristine pharmacodynamics, was recently associated with neurotoxicity after prolonged vincristine treatment. This association was not replicated in our Spanish population during induction phase. To test the possibility that other variants in genes involved in vincristine pharmacodynamics were associated with vincristine neuropathy in early phases of the treatment, we evaluated the correlation with toxicity of 24 polymorphisms in 9 key genes in a large cohort of 152 Spanish children with B-ALL homogeneously treated...
December 2019: Pharmacogenomics Journal
https://read.qxmd.com/read/29458787/a-systematic-review-of-the-safety-profile-of-the-different-combinations-of-fluoropyrimidines-and-oxaliplatin-in-the-treatment-of-colorectal-cancer-patients
#2
REVIEW
Chiara Baratelli, Clizia Zichi, Massimo Di Maio, Maria Pia Brizzi, Cristina Sonetto, Giorgio Vittorio Scagliotti, Marco Tampellini
The available fluoropyrimidines and oxaliplatin combinations for colorectal cancer patients have different safety profiles. The aim of this systematic review was to compare their toxicities. The eligible studies were classified as: no bolus; 5-FU single bolus; 5-FU double bolus; capecitabine. We calculated the incidence of "any-grade" and "severe" toxicity for haematological and non-haematological adverse events of each group. We identified 184 treatment groups; compared to 5-FU double bolus, except for high-grade anaemia, all the groups showed reduced risk of haematological toxicities, with the most relevant advantages for single bolus regimens...
February 2018: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/9559486/low-prevalence-of-long-term-complications-in-non-insulin-dependent-diabetes-mellitus-in-france-a-multicenter-study-codiab-inserm-zeneca-pharma-study-group
#3
MULTICENTER STUDY
C Delcourt, F Vauzelle-Kervroedan, G Cathelineau, L Papoz
The aim of this study was to assess the prevalence of long-term complications in a large sample of French NIDDM patients. Therefore, 427 NIDDM patients 35-74 years old were recruited in ten centers. Standardized clinical criteria and central reading for retinal and electrocardiographic changes were used to assess the presence of complications. The prevalence rates of complications were 29.7% and 3.3% for background and proliferative retinopathy; 21.8%, 6.1%, and 2.8% for microalbuminuria, proteinuria, and renal insufficiency; 19...
March 1998: Journal of Diabetes and its Complications
https://read.qxmd.com/read/4446960/-ultrastructural-study-of-pheripheral-nerve-in-16-diabetics-without-neuropathy-comparisons-with-16-diabetic-neuropathies-and-16-non-diabetic-neuropathies-author-s-transl
#4
JOURNAL ARTICLE
C Vital, M Le Blanc, J M Vallat, M Cocquet, M Vallat, J C Roques
No abstract text is available yet for this article.
1974: Acta Neuropathologica
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.